A30P and A53T mutations in the gene encoding alpha-synuclein—a presynaptic protein—are the most frequently identified genetic causes of Parkinson’s disease (PD). Aberrant alpha-synuclein likely plays central roles in dopaminergic neuronal death and motor symptoms in PD. This study investigated the protein phosphorylation profile in early-stage PD through phosphoproteomic analyses of tissue samples from the substantia nigra pars compacta (SNpc) of 6-month-old alpha-synuclein transgenic mice (A30P/A53T double-mutant human alpha-synuclein; hm2α-SYN-39 strain). We identified 5351 phosphorylation sites in 2136 phosphoproteins. Of these, 357 upregulated sites in 245 proteins and 50 downregulated sites in 46 proteins were differentially phosphorylated between alpha-synuclein transgenic and wildtype mice. Bioinformatic analyses, including Gene Ontology, Kyoto Encyclopedia of Genes and Genomes pathway enrichment, and motif analyses, were used to elucidate the molecular and cellular mechanisms underlying double-mutant human alpha-synuclein overexpression. Scansite-based computational analysis and prediction of differentially quantitated phosphoproteins identified the neuronal protein cyclin-dependent kinase 5 (Cdk5) as the most significantly enriched kinase. Biochemical experiments suggested that the p25/Cdk5 pathway was activated in an MPP+-induced cell culture model and MPTP-induced mouse model. Moreover, Cdk5 could directly phosphorylate the Ank2 protein at Ser1889 in vitro. Therefore, quantitative phosphoproteomic using an alpha-synuclein transgenic mouse model offers a powerful approach for elucidating the protein phosphorylation mechanism underlying SNpc dopaminergic neuronal death in an animal model of PD.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
The MS proteomics data have been deposited in the ProteomeXchange Consortium via the PRIDE partner repository, with the dataset identifier PXD013965.
Bulat V, Rast M, Pielage J (2014) Presynaptic CK2 promotes synapse organization and stability by targeting Ankyrin2. J Cell Biol 204(1):77–94. https://doi.org/10.1083/jcb.201305134
Chu Y, Morfini GA, Langhamer LB, He Y, Brady ST, Kordower JH (2012) Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain 135(Pt 7):2058–2073. https://doi.org/10.1093/brain/aws133
Cortes N, Guzman-Martinez L, Andrade V, Gonzalez A, Maccioni RB (2019) CDK5: A Unique CDK and Its Multiple Roles in the Nervous System. J Alzheimers Dis 68(3):843–855. https://doi.org/10.3233/JAD-180792
Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH (2003) Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40(3):471–483
Dhavan R, Tsai LH (2001) A decade of CDK5. Nat Rev Mol Cell Biol 2(10):749–759. https://doi.org/10.1038/35096019
Diogenes MJ, Dias RB, Rombo DM, Vicente Miranda H, Maiolino F, Guerreiro P, Nasstrom T, Franquelim HG, Oliveira LM, Castanho MA, Lannfelt L, Bergstrom J, Ingelsson M, Quintas A, Sebastiao AM, Lopes LV, Outeiro TF (2012) Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci 32(34):11750–11762. https://doi.org/10.1523/JNEUROSCI.0234-12.2012
Duka V, Lee JH, Credle J, Wills J, Oaks A, Smolinsky C, Shah K, Mash DC, Masliah E, Sidhu A (2013) Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases. PLoS ONE 8(9):e75025. https://doi.org/10.1371/journal.pone.0075025
Gomez-Santos C, Ferrer I, Reiriz J, Vinals F, Barrachina M, Ambrosio S (2002) MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. Brain Res 935(1–2):32–39. https://doi.org/10.1016/s0006-8993(02)02422-8
Gramage E, Herradon G, Martin YB, Vicente-Rodriguez M, Rojo L, Gnekow H, Barbero A, Perez-Garcia C (2013) Differential phosphoproteome of the striatum from pleiotrophin knockout and midkine knockout mice treated with amphetamine: correlations with amphetamine-induced neurotoxicity. Toxicology 306:147–156. https://doi.org/10.1016/j.tox.2013.02.013
Gureviciene I, Gurevicius K, Tanila H (2007) Role of alpha-synuclein in synaptic glutamate release. Neurobiol Dis 28(1):83–89. https://doi.org/10.1016/j.nbd.2007.06.016
Hunter T (2007) The age of crosstalk: phosphorylation, ubiquitination, and beyond. Mol Cell 28(5):730–738. https://doi.org/10.1016/j.molcel.2007.11.019
Huttlin EL, Jedrychowski MP, Elias JE, Goswami T, Rad R, Beausoleil SA, Villen J, Haas W, Sowa ME, Gygi SP (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143(7):1174–1189. https://doi.org/10.1016/j.cell.2010.12.001
Ingelsson M (2016) Alpha-synuclein oligomers-neurotoxic molecules in Parkinson's Disease and other lewy body disorders. Front Neurosci 10:408. https://doi.org/10.3389/fnins.2016.00408
Iwata A, Maruyama M, Kanazawa I, Nukina N (2001) alpha-Synuclein affects the MAPK pathway and accelerates cell death. J Biol Chem 276(48):45320–45329. https://doi.org/10.1074/jbc.M103736200
Jiao FJ, Wang QZ, Zhang P, Yan JG, Zhang Z, He F, Zhang Q, Lv ZX, Peng X, Cai HW, Tian B (2017) CDK5-mediated phosphorylation of XBP1s contributes to its nuclear translocation and activation in MPP(+)-induced Parkinson's disease model. Sci Rep 7(1):5622. https://doi.org/10.1038/s41598-017-06012-6
Kane LA, Youle RJ (2011) PINK1 and Parkin flag Miro to direct mitochondrial traffic. Cell 147(4):721–723. https://doi.org/10.1016/j.cell.2011.10.028
Kasai S, Torii S, Kakita A, Sogawa K (2015) Inhibitory PAS domain protein is a substrate of PINK1 and Parkin and mediates cell death in a Parkinson's disease model. Cell Death Dis 6:e1886. https://doi.org/10.1038/cddis.2015.243
Kim SH, Ryan TA (2010) CDK5 serves as a major control point in neurotransmitter release. Neuron 67(5):797–809. https://doi.org/10.1016/j.neuron.2010.08.003
Koch I, Schwarz H, Beuchle D, Goellner B, Langegger M, Aberle H (2008) Drosophila ankyrin 2 is required for synaptic stability. Neuron 58(2):210–222. https://doi.org/10.1016/j.neuron.2008.03.019
Li J, Uversky VN, Fink AL (2001) Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 40(38):11604–11613. https://doi.org/10.1021/bi010616g
Lorenzo DN, Badea A, Davis J, Hostettler J, He J, Zhong G, Zhuang X, Bennett V (2014) A PIK3C3-ankyrin-B-dynactin pathway promotes axonal growth and multiorganelle transport. J Cell Biol 207(6):735–752. https://doi.org/10.1083/jcb.201407063
McGregor MM, Nelson AB (2019) Circuit mechanisms of Parkinson's Disease. Neuron 101(6):1042–1056. https://doi.org/10.1016/j.neuron.2019.03.004
Nguyen LK, Kolch W, Kholodenko BN (2013) When ubiquitination meets phosphorylation: a systems biology perspective of EGFR/MAPK signalling. Cell Commun Signal 11:52. https://doi.org/10.1186/1478-811X-11-52
Obenauer JC, Cantley LC, Yaffe MB (2003) Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res 31 (13):3635–3641. https://doi.org/10.1093/nar/gkg584
Ono K, Ikemoto M, Kawarabayashi T, Ikeda M, Nishinakagawa T, Hosokawa M, Shoji M, Takahashi M, Nakashima M (2009) A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice. Parkinsonism Relat Disord 15(9):649–654. https://doi.org/10.1016/j.parkreldis.2009.03.002
Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402(6762):615–622. https://doi.org/10.1038/45159
Pickrell AM, Youle RJ (2015) The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron 85(2):257–273. https://doi.org/10.1016/j.neuron.2014.12.007
Qu D, Rashidian J, Mount MP, Aleyasin H, Parsanejad M, Lira A, Haque E, Zhang Y, Callaghan S, Daigle M, Rousseaux MW, Slack RS, Albert PR, Vincent I, Woulfe JM, Park DS (2007) Role of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson's disease. Neuron 55(1):37–52. https://doi.org/10.1016/j.neuron.2007.05.033
Richfield EK, Thiruchelvam MJ, Cory-Slechta DA, Wuertzer C, Gainetdinov RR, Caron MG, Di Monte DA, Federoff HJ (2002) Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp Neurol 175(1):35–48. https://doi.org/10.1006/exnr.2002.7882
Schmid AW, Fauvet B, Moniatte M, Lashuel HA (2013) Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Mol Cell Proteom 12(12):3543–3558. https://doi.org/10.1074/mcp.R113.032730
Smith PD, Crocker SJ, Jackson-Lewis V, Jordan-Sciutto KL, Hayley S, Mount MP, O'Hare MJ, Callaghan S, Slack RS, Przedborski S, Anisman H, Park DS (2003) Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 100(23):13650–13655. https://doi.org/10.1073/pnas.2232515100
Tanji K, Mori F, Mimura J, Itoh K, Kakita A, Takahashi H, Wakabayashi K (2010) Proteinase K-resistant alpha-synuclein is deposited in presynapses in human Lewy body disease and A53T alpha-synuclein transgenic mice. Acta Neuropathol 120(2):145–154. https://doi.org/10.1007/s00401-010-0676-z
Thiruchelvam MJ, Powers JM, Cory-Slechta DA, Richfield EK (2004) Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice. Eur J Neurosci 19(4):845–854. https://doi.org/10.1111/j.0953-816x.2004.03139.x
Triplett JC, Zhang Z, Sultana R, Cai J, Klein JB, Bueler H, Butterfield DA (2015) Quantitative expression proteomics and phosphoproteomics profile of brain from PINK1 knockout mice: insights into mechanisms of familial Parkinson's disease. J Neurochem 133(5):750–765. https://doi.org/10.1111/jnc.13039
Villen J, Gygi SP (2008) The SCX/IMAC enrichment approach for global phosphorylation analysis by mass spectrometry. Nat Protoc 3(10):1630–1638. https://doi.org/10.1038/nprot.2008.150
Wang X, Winter D, Ashrafi G, Schlehe J, Wong YL, Selkoe D, Rice S, Steen J, LaVoie MJ, Schwarz TL (2011) PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. Cell 147(4):893–906. https://doi.org/10.1016/j.cell.2011.10.018
Wang Q, Jiao F, Zhang P, Yan J, Zhang Z, He F, Zhang Q, Lv Z, Peng X, Cai H, Tian B (2018) CDK5-Mediated Phosphorylation-Dependent Ubiquitination and Degradation of E3 Ubiquitin Ligases GP78 Accelerates Neuronal Death in Parkinson's Disease. Mol Neurobiol 55(5):3709–3717. https://doi.org/10.1007/s12035-017-0579-2
Wen Y, Planel E, Herman M, Figueroa HY, Wang L, Liu L, Lau LF, Yu WH, Duff KE (2008) Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J Neurosci 28(10):2624–2632. https://doi.org/10.1523/JNEUROSCI.5245-07.2008
Wen Z, Shu Y, Gao C, Wang X, Qi G, Zhang P, Li M, Shi J, Tian B (2014) CDK5-mediated phosphorylation and autophagy of RKIP regulate neuronal death in Parkinson's disease. Neurobiol Aging 35(12):2870–2880. https://doi.org/10.1016/j.neurobiolaging.2014.05.034
Wong AS, Lee RH, Cheung AY, Yeung PK, Chung SK, Cheung ZH, Ip NY (2011) Cdk5-mediated phosphorylation of endophilin B1 is required for induced autophagy in models of Parkinson's disease. Nat Cell Biol 13(5):568–579. https://doi.org/10.1038/ncb2217
Yan J, Zhang P, Jiao F, Wang Q, He F, Zhang Q, Zhang Z, Lv Z, Peng X, Cai H, Tian B (2017) Quantitative proteomics in A30P*A53T alpha-synuclein transgenic mice reveals upregulation of Sel1l. PLoS ONE 12(8):e0182092. https://doi.org/10.1371/journal.pone.0182092
Yousuf MA, Tan C, Torres-Altoro MI, Lu FM, Plautz E, Zhang S, Takahashi M, Hernandez A, Kernie SG, Plattner F, Bibb JA (2016) Involvement of aberrant cyclin-dependent kinase 5/p25 activity in experimental traumatic brain injury. J Neurochem 138(2):317–327. https://doi.org/10.1111/jnc.13620
We also thank the members of the PTM BioLabs for technical support and helpful discussion and we would like to thank Xiaojun Peng (Department of Proteomics, PTM BioLabs, Inc.) for the guidance about bioinformatics analyses.
This work was supported financially by grants from National Natural Science Foundation of China (No. 31571044,31871073 to B.T., and No. 31600821 to P.Z.), Program for New Century Excellent Talents in University (No. NCET-10–0415 to B.T.), China Postdoctoral Scientific Foundation (No. 2018T110774 to P.Z.), Natural Science Foundation of Hubei Province (No. 2017CFB465 to P.Z.), Educational Commission of Hubei Province of China (No. D20182102 to P.Z.) and the Fundamental Research Funds for the Central Universities (HUST: 2019kfyXJJS081 to P.Z.).
Conflict of interest
The authors declare that they have no conflict of interest.
Research Involving Animal Participants
All the procedures were in line with institutional guidelines and were approved by the Animal Care and Use Committee of the core animal facility (Tongji Medical College, Huazhong University of Science and Technology, China).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
He, F., Qi, G., Zhang, Q. et al. Quantitative Phosphoproteomic Analysis in Alpha-Synuclein Transgenic Mice Reveals the Involvement of Aberrant p25/Cdk5 Signaling in Early-stage Parkinson’s Disease. Cell Mol Neurobiol 40, 897–909 (2020). https://doi.org/10.1007/s10571-019-00780-7
- Parkinson's disease
- Substantia nigra pars compacta
- Cyclin-dependent kinase 5